Publications Banner

Publications

Publications

Below is a selection of publications that Global Vaccine Data Network™ (GVDN™) partners have been involved in. These publications address various aspects of vaccine safety, with a focus on collaborative observation studies that use large healthcare databases to look for rare adverse events following vaccination. The publications are presented geographically by World Health Organization (WHO) region to demonstrate the global representation of partners in the GVDN™.

2021

  • Black SB, Law B, Chen RT, Dekker CL, Sturkenboom M, Huang W-T, et al. The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine. 2021;39(19):2712-8. PMC7936550
  • Dodd C, Andrews N, Petousis-Harris H, Sturkenboom M, Omer SB, Black S. Methodological frontiers in vaccine safety: Qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions. BMJ Glob Health. 2021;6(Suppl 2):e003540. PMID34011501

2020

  • Petousis-Harris H. Assessing the safety of COVID-19 vaccines: A primer. Drug Saf. 2020;43(12):1205-10. PMID3299731
  • Petousis-Harris H, Dodd CN. Progress toward a Global Vaccine Data Network. Pediatr Infect Dis J. 2020;39(11):1023-5. PMID32502124

2018

  • Guillard-Maure C, Elango V, Black S, Perez-Vilar S, Castro JL, Bravo-Alcántara P, et al. Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: The global vaccine safety multi country collaboration initiative. 2018;36(3):355-62. PMID28780118
  • Perez-Vilar S, Weibel D, Sturkenboom M, Black S, Maure C, Castro JL, et al. Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine. 2018;36(3):347-54. PMC5656178
  • Weibel D, Sturkenboom M, Black S, de Ridder M, Dodd C, Bonhoeffer J, et al. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment. Vaccine. 2018;36(41):6202-11. PMID30122647

2013

  • Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013;31(40):4448-58. PMID23770307

2022

  • Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. Epub ahead of print 2022 Apr 20. PMID 35442390 

2020

  • Bollaerts K, Ledent E, de Smedt T, Weibel D, Emborg H-D, Danieli G, et al. ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling. Vaccine. 2020;38:B65-75. PMID31677947
  • Dodd C, de Ridder M, Weibel D, Mahaux O, Haguinet F, de Smedt T, et al. ADVANCE system testing: Estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data. Vaccine. 2020;38:B47-55. PMID32280043
  • Simpson CR, Robertson C, Vasileiou E, McMenamin J, Gunson R, Ritchie LD, et al. Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data. BMJ Open. 2020;10(6):e039097. PMID32565483
  • Weibel D, Dodd C, Mahaux O, Haguinet F, De Smedt T, Duarte-Salles T, et al. ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination. Vaccine. 2020;38:B38-46. PMID31677946

2018

  • Artama M, Rinta-Kokko H, Nohynek H, Jokinen J, Palmu AA. Register-Based ecologic evaluation of safety signals related to pneumococcal conjugate vaccine in children. Curr Drug Saf. 2018;13(2):107-12. PMID29623819
  • Hviid A, Svanström H, Scheller NM, Grönlund O, Pasternak B, Arnheim-Dahlström L. Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. J Intern Med. 2018;283(2):154-65. PMID29044769
  • Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine. 2018;36(39):5926-33. PMID30115524

2017

  • Skufca J, Ollgren J, Ruokokoski E, Lyytikäinen O, Nohynek H. Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002–2012. Papillomavirus Res. 2017;3:91-6. PMID28720463

2015

  • Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54-61. PMID25562266

2014

  • Romio S, Weibel D, Dieleman JP, Olberg HK, de Vries CS, Sammon C, et al. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: A multinational self-controlled case series in Europe. PLoS One. 2014;9(1):e82222. PMC3880265

2013

  • Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study. BMJ. 2013;347:f5906. PMID24108159

2012

  • Andrews N, Stowe J, Miller E, Svanström H, Johansen K, Bonhoeffer J, et al. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine. 2012;30(19):3042-6. PMID21699947
  • Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. Plos One. 2012;7(3):e33536. PMID22470453

2011

  • Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ. 2011;343:d3908. PMID21750072

2022

  • Fell DB, Dhinsa T, Alton GD, Török E, Dimanlig-Cruz S, Regan AK, et al. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA. Epub ahead of print 2022, Mar 24. PMID35323842

2019

  • Edwards K, Hanquet G, Black S, Mignot E, Jankosky C, Shimabukuro T, et al. Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. Biologicals. 2019;60:1-7. PMID31130313

2016

  • Baxter R, Lewis E, Goddard K, Fireman B, Bakshi N, DeStefano F, et al. Acute demyelinating events following vaccines: A case-centered analysis. Clin Infect Dis. 2016;63(11):1456-62. PMID27585798
  • DeSilva M, Vazquez-Benitez G, Nordin JD, Lipkind HS, Romitti PA, DeStefano F, et al. Tdap vaccination during pregnancy and microcephaly and other structural birth defects in offspring. JAMA. 2016;316(17):1823-5. PMID27802536

2013

  • Greene SK, Rett MD, Vellozzi C, Li L, Kulldorff M, Marcy SM, et al. Guillain-Barré syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: A case-centered analysis in the Vaccine Safety Datalink, 2009-2011. PLoS One. 2013;8(6):e67185. PMC3694016

2022

  • Lai FTT, Li X, Peng K, Huang L, Ip P, Tong X, et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine. Ann Intern Med. 2022;175(3):362-70. PMID35073155

2020

  • Liu C-H, Yeh Y-C, Huang W-T, Chie W-C, Chan KA. Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study. Vaccine. 2020;38(11):2495-502. PMID32046891

2019

  • Petousis-Harris H, Jiang Y, Yu L, Watson D, Walls T, Turner N, et al. A retrospective cohort study of safety outcomes in New Zealand infants exposed to Tdap vaccine in utero. Vaccines. 2019;7(4):147. PMC6963487

2018

  • Griffin JB, Yu L, Watson D, Turner N, Walls T, Howe AS, et al. Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. Vaccine. 2018;36(34):5173-9. PMID30031662

2011

  • Huang W-C, Huang L-M, Chang IS, Tsai F-Y, Chang L-Y. Varicella breakthrough infection and vaccine effectiveness in Taiwan. Vaccine. 2011;29(15):2756-60. PMID32736940